Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC’s “vague standard” on trial

This article was originally published in The Tan Sheet

Executive Summary

The Federal Trade Commission "is unlawfully trying to suppress...commercial free speech protected by the First Amendment through imposition of a vague substantiation standard for advertised claims," according to a lawsuit filed in Utah district court by Relacore marketer Carter-Reed Dec. 13. Claims for C-R's stress-reliever and "belly-fat" reducer dietary supplement initially were cited by the National Advertising Division, and subsequently referred to FTC (1"The Tan Sheet" June 28, 2004, In Brief). FTC then threatened Carter-Reed with law enforcement action for making false and misleading claims for the cortisol-containing product. The firm is seeking to enjoin the FTC from suppressing advertised claims for Relacore under the FTC Act's "competent and reliable scientific evidence" standard...

You may also be interested in...

NAD sheds weight claims, adds to FTC’s load

Print and broadcast advertising for Carter-Reed's Relacore has been referred to the Federal Trade Commission after the firm's "failure to provide a substantive response" to NAD's inquiry, the watchdog group states in an upcoming Case Reports. The Council of Better Business Bureaus division came across the claims "A natural feel-good pill called Relacore might be the perfect answer to belly fat" and "The most significant weight-control advancement in more than a decade" during a routine review. Carter-Reed said "it had prepared a confidential submission for NAD," but never submitted the statement...

Vaccine Hesitancy May Drive Distribution Priorities For Early COVID-19 Supply

ACIP defers vote on who should be inoculated first until it has data on a specific product, but vaccine acceptance among different groups could be weighed as factor in setting distribution priorities, committee members suggest.

China’s Cosmetic Animal-Testing Exemption ‘Not A Terribly Meaningful Solution’ – PCPC

The Personal Care Products Council’s Francine Lamoriello, EVP of global strategies, discusses shortcomings of a proposed animal-testing exemption for imported general cosmetics under a key implementing regulation drafted for China’s new cosmetics oversight framework.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts